Unique ID issued by UMIN | UMIN000044811 |
---|---|
Receipt number | R000050183 |
Scientific Title | Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients |
Date of disclosure of the study information | 2021/07/09 |
Last modified on | 2023/01/09 13:29:39 |
Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients
Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients
Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients
Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients
Japan |
Non small cell lung cancer
Pneumology |
Malignancy
NO
Investigating the efficacy and safety of ipilimumab plus nivolumab in non-small cell lung cancer
Safety,Efficacy
Progression free survival
Observational
20 | years-old | <= |
100 | years-old | >= |
Male and Female
(1) Patients aged 20 years or older with PS 0-2 at the time of consent
(2) Patients with advanced or recurrent non-small cell lung cancer that is not curatively resectable
(3) Patients with evaluable lesions by RECIST (version 1.1)
(4) Patients who are scheduled to receive combination therapy including ipilimumab and nivolumab.
(5) Patients who have been fully informed about the contents of this clinical study and have given their free written consent.
(5) Patients who have been fully informed about the contents of this clinical study and have given their free written consent.
(1) Patients with active multiple cancers (hormonal therapy for prostate cancer and breast cancer is acceptable)
(2)Patients with a history of treatment with systemic chemotherapy or immune checkpoint inhibitors (However, molecularly targeted cancer drugs for patients with positive driver gene mutations and postoperative adjuvant chemotherapy for patients with postoperative recurrence are acceptable)
(3)Other patients who are judged inappropriate by the physician in charge.
50
1st name | Tadaaki |
Middle name | |
Last name | Yamada |
Kyoto Prefectural University of Medicine
Pulmonary Medicine
6020841
465, Kajii-cho, Kamigyo-ku, Kyoto
0752515513
tayamada@koto.kpu-m.ac.jp
1st name | Yuki |
Middle name | |
Last name | Katayama |
Kyoto Prefectural University of Medicine
Pulmonary Medicine
6020841
465, Kajii-cho, Kamigyo-ku, Kyoto
0752515513
ktym2487@koto.kpu-m.ac.jp
Kyoto Prefectural University of Medicine
None
Other
Kyoto Prefectural University of Medicine
465, Kajii-cho, Kamigyo-ku, Kyoto
0752515337
rinri@koto.kpu-m.ac.jp
NO
2021 | Year | 07 | Month | 09 | Day |
Unpublished
Open public recruiting
2021 | Year | 01 | Month | 05 | Day |
2021 | Year | 02 | Month | 24 | Day |
2021 | Year | 04 | Month | 01 | Day |
2023 | Year | 09 | Month | 30 | Day |
None
2021 | Year | 07 | Month | 09 | Day |
2023 | Year | 01 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050183
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |